Want to see NZ:AFT full AI Analyst Report?
AFT Pharmaceuticals Ltd. (AFT) Ratios
AFT Pharmaceuticals Ltd. Ratios
NZ:AFT's free cash flow for Q4 2026 was $-11.19M. For the 2026 fiscal year, NZ:AFT's free cash flow was decreased by $-52.00K and operating cash flow was $-11.14M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.24 | 2.50 | 2.30 | 2.38 | 2.67 |
| Quick Ratio | 1.12 | 1.38 | 1.23 | 1.31 | 1.52 |
| Cash Ratio | 0.15 | 0.26 | 0.26 | 0.12 | 0.27 |
| Solvency Ratio | 0.17 | 0.20 | 0.23 | 0.17 | 0.32 |
| Operating Cash Flow Ratio | -0.18 | 0.30 | 0.63 | 0.29 | 0.49 |
| Short-Term Operating Cash Flow Coverage | -1.01 | 12.17 | 0.00 | 4.73 | 3.54 |
| Net Current Asset Value | $ 40.60M | $ 35.60M | $ 28.27M | $ 19.80M | $ 12.53M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.18 | 0.19 | 0.26 | 0.32 |
| Debt-to-Equity Ratio | 0.49 | 0.31 | 0.37 | 0.52 | 0.65 |
| Debt-to-Capital Ratio | 0.33 | 0.24 | 0.27 | 0.34 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.26 | 0.21 | 0.24 | 0.31 | 0.35 |
| Financial Leverage Ratio | 1.97 | 1.74 | 1.88 | 2.02 | 2.04 |
| Debt Service Coverage Ratio | 1.48 | 4.33 | 5.78 | 2.86 | 3.63 |
| Interest Coverage Ratio | 9.98 | 4.15 | 5.51 | 6.85 | 8.37 |
| Debt to Market Cap | 0.14 | 0.09 | 0.08 | 0.10 | 0.10 |
| Interest Debt Per Share | 0.54 | 0.31 | 0.34 | 0.39 | 0.41 |
| Net Debt to EBITDA | 1.54 | 0.88 | 0.73 | 1.63 | 1.47 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.40% | 43.40% | 44.78% | 46.59% | 47.40% |
| EBIT Margin | 9.76% | 9.18% | 13.25% | 11.92% | 16.21% |
| EBITDA Margin | 11.21% | 10.47% | 14.29% | 13.02% | 17.01% |
| Operating Profit Margin | 9.76% | 5.69% | 10.47% | 12.56% | 15.65% |
| Pretax Profit Margin | 8.59% | 7.80% | 11.35% | 10.09% | 14.34% |
| Net Profit Margin | 5.78% | 5.82% | 8.04% | 6.80% | 15.23% |
| Continuous Operations Profit Margin | 5.53% | 5.55% | 8.04% | 6.80% | 15.23% |
| Net Income Per EBT | 67.34% | 74.60% | 70.89% | 67.43% | 106.22% |
| EBT Per EBIT | 88.01% | 137.05% | 108.38% | 80.32% | 91.64% |
| Return on Assets (ROA) | 6.79% | 7.04% | 9.45% | 7.20% | 15.59% |
| Return on Equity (ROE) | 13.36% | 12.25% | 17.78% | 14.54% | 31.85% |
| Return on Capital Employed (ROCE) | 16.50% | 9.24% | 17.05% | 18.16% | 20.75% |
| Return on Invested Capital (ROIC) | 9.80% | 6.48% | 12.00% | 17.14% | 28.17% |
| Return on Tangible Assets | 9.65% | 7.84% | 10.49% | 8.08% | 17.83% |
| Earnings Yield | 4.18% | 4.24% | 4.56% | 2.97% | 5.28% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.97 | 4.76 | 4.73 | 3.95 | 4.36 |
| Payables Turnover | 4.87 | 4.63 | 4.23 | 3.77 | 5.68 |
| Inventory Turnover | 1.95 | 2.40 | 2.18 | 1.97 | 2.05 |
| Fixed Asset Turnover | 75.76 | 63.23 | 50.78 | 46.55 | 38.78 |
| Asset Turnover | 1.17 | 1.21 | 1.17 | 1.06 | 1.02 |
| Working Capital Turnover Ratio | 3.46 | 3.29 | 3.39 | 3.03 | 3.09 |
| Cash Conversion Cycle | 204.66 | 150.04 | 157.97 | 180.50 | 197.79 |
| Days of Sales Outstanding | 92.05 | 76.73 | 77.14 | 92.32 | 83.65 |
| Days of Inventory Outstanding | 187.54 | 152.13 | 167.13 | 184.98 | 178.40 |
| Days of Payables Outstanding | 74.93 | 78.82 | 86.29 | 96.79 | 64.27 |
| Operating Cycle | 279.59 | 228.85 | 244.26 | 277.29 | 262.05 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.11 | 0.13 | 0.28 | 0.11 | 0.13 |
| Free Cash Flow Per Share | -0.11 | 0.06 | 0.18 | 0.11 | 0.13 |
| Dividend Paid and CapEx Coverage Ratio | -5.87 | 1.53 | 2.70 | 59.03 | 43.02 |
| Capital Expenditure Coverage Ratio | -101.29 | 1.90 | 3.03 | 59.03 | 43.02 |
| Operating Cash Flow Coverage Ratio | -0.22 | 0.44 | 0.90 | 0.31 | 0.35 |
| Operating Cash Flow to Sales Ratio | -0.05 | 0.06 | 0.15 | 0.07 | 0.11 |
| Free Cash Flow Yield | -3.37% | 2.21% | 5.64% | 3.19% | 3.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.00 | 24.45 | 21.95 | 33.64 | 18.93 |
| Price-to-Sales (P/S) Ratio | 1.38 | 1.37 | 1.77 | 2.29 | 2.88 |
| Price-to-Book (P/B) Ratio | 3.19 | 2.89 | 3.90 | 4.89 | 6.03 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -29.69 | 45.32 | 17.72 | 31.35 | 27.18 |
| Price-to-Operating Cash Flow Ratio | -29.99 | 21.41 | 11.87 | 30.82 | 26.54 |
| Price-to-Earnings Growth (PEG) Ratio | 0.88 | -0.92 | 0.44 | -0.71 | 0.12 |
| Enterprise Value Multiple | 13.88 | 13.98 | 13.09 | 19.21 | 18.42 |
| Enterprise Value | 396.22M | 300.98M | 362.81M | 391.74M | 408.23M |
| EV to EBITDA | 13.88 | 13.98 | 13.09 | 19.21 | 18.42 |
| EV to Sales | 1.56 | 1.46 | 1.87 | 2.50 | 3.13 |
| EV to Free Cash Flow | -33.39 | 48.35 | 18.77 | 34.27 | 29.53 |
| EV to Operating Cash Flow | -33.72 | 22.84 | 12.57 | 33.69 | 28.85 |
| Tangible Book Value Per Share | 0.43 | 0.76 | 0.68 | 0.54 | 0.44 |
| Shareholders’ Equity Per Share | 1.05 | 0.93 | 0.84 | 0.70 | 0.59 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.36 | 0.29 | 0.29 | 0.33 | -0.06 |
| Revenue Per Share | 2.43 | 1.96 | 1.85 | 1.49 | 1.24 |
| Net Income Per Share | 0.14 | 0.11 | 0.15 | 0.10 | 0.19 |
| Tax Burden | 0.67 | 0.75 | 0.71 | 0.67 | 1.06 |
| Interest Burden | 0.88 | 0.85 | 0.86 | 0.85 | 0.88 |
| Research & Development to Revenue | 0.04 | 0.06 | 0.04 | 0.04 | 0.04 |
| SG&A to Revenue | 0.29 | 0.31 | 0.06 | 0.07 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.80 | 1.10 | 1.85 | 1.09 | 0.71 |
Currency in NZD
